Medically reviewed by
Betsy Greenleaf, DO
Board-Certified OB/GYN & Urogynecologist; Empire Director of Anti-Aging PDE5 inhibitors are the medications most people picture when they think of treatment for erectile dysfunction. Sildenafil — better known as Viagra — was the first to reach the market in 1998, and the class it launched has since become the cornerstone of how clinicians manage erectile dysfunction. For providers, the value is not in memorizing brand names but in understanding the underlying physiology: why these drugs work, why they sometimes do not, and where the genuine dangers lie.
This guide situates PDE5 inhibitors within the broader field of sexual health and dysfunction and is written for clinicians who want an accurate, practical overview. It is clinical education, not medical advice, and nothing here should be read as a treatment recommendation, dosing protocol, or substitute for current FDA labeling.
What are PDE5 inhibitors?
PDE5 inhibitors are a class of oral drugs that have become the first-line treatment for erectile dysfunction. Erectile dysfunction is the most common sexual dysfunction in men, affecting over half of men between the ages of 40 and 70, and for the large majority of those patients an oral PDE5 inhibitor is where treatment begins. Their arrival fundamentally changed the field: an effective, well-tolerated pill replaced more invasive first-line options and brought a great many men into care who would never have pursued treatment otherwise.
There are four FDA-approved agents in the class — sildenafil (Viagra), tadalafil (Cialis), vardenafil (Levitra), and avanafil (Stendra). They share one mechanism but differ in how quickly they work and how long their effect lasts, which is the practical basis for choosing among them. Crucially, all of them share an important limitation that patients frequently misunderstand: a PDE5 inhibitor is not an on-demand switch that produces an erection by itself. As Dr. Greenleaf puts it in Empire's course, "without brain stimulation, all the Viagra in the world will not function." The drug facilitates a physiological process; it does not initiate it.
How PDE5 inhibitors work
To understand the class, start with how a normal erection happens. During sexual stimulation, nerves and the vascular endothelium in the penis release nitric oxide, a neurotransmitter that relaxes the smooth muscle in the blood vessel walls. That relaxation allows the corpora cavernosa to fill with blood and engorge. As the sinusoids expand they compress the emissary veins that normally drain the penis, trapping blood inside and sustaining rigidity. The entire cascade is driven by smooth muscle relaxation, and that relaxation is mediated by nitric oxide.
Nitric oxide does its work through a second messenger called cyclic guanosine monophosphate (cyclic GMP). When nitric oxide is released, it activates the enzyme guanylate cyclase, which raises cyclic GMP levels. Cyclic GMP is the molecule that actually relaxes and dilates the blood vessels, increasing penile blood flow. The body then needs a way to switch this signal off — and that is the job of the enzyme phosphodiesterase type 5.
PDE5 is found in the smooth muscle cells of blood vessels, including those of the penis and the lungs. Its normal function is to break down cyclic GMP, ending vasodilation and allowing the tissue to return to a resting state. PDE5 inhibitors block this enzyme. By inhibiting PDE5, the drug prevents the breakdown of cyclic GMP, so cyclic GMP accumulates, vasodilation is prolonged, and blood flow into the penis is enhanced. The result is improved ability to achieve and maintain an erection.
The agents: sildenafil, tadalafil, vardenafil, avanafil
All four agents inhibit PDE5, but their pharmacokinetics differ, and that is what guides selection for a given patient and a given situation. The practical distinctions are onset and duration.
- Sildenafil (Viagra) — the original PDE5 inhibitor, approved in 1998. It has a relatively quick onset and a duration measured in hours, making it the prototypical on-demand, plan-ahead agent. Absorption can be slowed by a high-fat meal.
- Tadalafil (Cialis) — approved in the early 2000s, tadalafil is distinguished by its much longer duration of action, which can extend over a day or more. This longer window allows for more spontaneity and supports lower-dose daily regimens in addition to on-demand use.
- Vardenafil (Levitra) — approved in 2003, vardenafil is broadly comparable to sildenafil in onset and duration and offers an alternative for patients who do not tolerate or respond to it.
- Avanafil (Stendra) — approved in 2012, avanafil is the newest of the class and is notable for its rapid onset, positioning it as a fast-acting on-demand option.
The headline contrast for most patients is sildenafil versus tadalafil: fast and shorter-acting versus slower and much longer-acting. Because that choice drives so many real-world decisions, we cover it in depth in our companion guide to Viagra vs Cialis. Exact doses, titration, and how to convert between agents belong to current FDA labeling and individualized judgment, and the prescribing detail is taught in Empire's course rather than reproduced here.
| Agent (brand) | Approved | Onset | Relative duration |
|---|---|---|---|
| Sildenafil (Viagra) | 1998 | Relatively quick | Several hours |
| Tadalafil (Cialis) | Early 2000s | Moderate | Longest — up to ~36 hours |
| Vardenafil (Levitra) | 2003 | Relatively quick | Several hours |
| Avanafil (Stendra) | 2012 | Rapid | Several hours |
Efficacy and evidence
Among treatments for erectile dysfunction, PDE5 inhibitors have the strongest and most established evidence base, which is precisely why they sit at the front line. They are effective across a wide range of underlying causes — vascular, metabolic, and psychogenic — and have been validated in large trials and decades of real-world use. Treatment response is commonly tracked with validated instruments such as the International Index of Erectile Function (IIEF), the 15-item questionnaire considered the gold standard for assessing erectile function and monitoring how well therapy is working.
Two honest caveats temper the picture. First, efficacy depends on intact arousal physiology: because these drugs only amplify a nitric-oxide signal that sexual stimulation has to generate, they underperform when the limiting factor is desire, anxiety, or a hostile nervous-system state rather than blood flow. Second, a meaningful minority of men do not respond adequately to oral therapy — particularly those with severe vascular disease, significant neurologic injury, or post-prostatectomy changes. For these non-responders, the diagnostic and treatment pathway moves beyond the pill, which is the subject of the final sections below.
Side effects and safety
For most patients, PDE5 inhibitors are well tolerated, and the common side effects follow directly from the mechanism: the same vasodilation that helps in the penis occurs to a lesser degree elsewhere. The frequently reported effects are headache, facial flushing, nasal congestion, indigestion, and transient visual changes — classically a temporary bluish tint to vision with sildenafil. These are usually mild and self-limited.
Two further safety considerations deserve emphasis. Alpha-blockers — commonly prescribed for benign prostatic hyperplasia and hypertension — also lower blood pressure and require caution when combined with a PDE5 inhibitor, typically with attention to timing and dose. And although rare, priapism — a prolonged, painful erection — is a urologic emergency: a sustained erection that does not resolve requires urgent evaluation, because untreated ischemic priapism can cause permanent damage.
There is also a broader clinical insight that providers must not miss. Erectile dysfunction is frequently the "canary in the coal mine" for cardiovascular disease. Penile arteries are small, and they often reveal endothelial dysfunction years before larger coronary vessels do. Men who develop erectile dysfunction carry a measurably higher subsequent risk of cardiovascular events. A request for a PDE5 inhibitor is therefore also an opportunity — and an obligation — to assess cardiovascular risk and, where appropriate, coordinate a cardiology evaluation rather than simply hand over a prescription.
Who it suits — and who it doesn't
PDE5 inhibitors suit the large population of men whose erectile dysfunction stems from the common drivers — vascular disease, diabetes, age-related changes, and psychogenic factors — and who have intact arousal and no contraindications. For these patients, an oral agent is the appropriate, evidence-backed first step, often paired with the lifestyle measures that address the root causes of erectile dysfunction: exercise, weight loss, smoking cessation, and stress reduction.
The class is not appropriate, or requires real caution, in several groups. The absolute exclusion is any patient on nitrates. Caution applies to men on alpha-blockers, those with significant or unstable cardiovascular disease, and patients with certain other comorbidities defined in labeling. Just as important is recognizing the patients for whom a pill is the wrong primary target altogether: when the limiting problem is low desire rather than blood flow, a PDE5 inhibitor will disappoint. As Dr. Greenleaf reminds clinicians, many patients believe Viagra is "the horny pill," but it is only a blood-flow agent and will not work unless the brain is engaged. Those patients are better served by addressing stress, relationship factors, hormones, or centrally acting options — topics covered in the guides on hormones and sexual function and the melanocortin peptide PT-141, which acts centrally to increase desire and arousal.
What to do when they fail
When an adequately trialed PDE5 inhibitor does not work, the answer is rarely to abandon treatment — it is to re-evaluate and step up. The first move is to confirm the patient was set up to succeed: correct dosing, adequate sexual stimulation, attention to absorption (a heavy meal can blunt sildenafil), and an honest look at whether desire, anxiety, or relationship dynamics are the real limiting factor. Many "failures" are really under-dosing or unmet arousal needs rather than true non-response.
For genuine non-responders, second-line options exist and are effective. Vacuum erection devices are a non-prescription, non-pharmacologic option that works for a broad range of underlying causes. Intracavernosal injection therapy — including agents such as alprostadil and compounded combinations — produces an erection through a different mechanism and is effective in a high percentage of men who do not respond to oral drugs, including some with significant vascular disease. Penile implants are a durable surgical option with high satisfaction for men who have exhausted or cannot tolerate other treatments. These next-line therapies, their mechanisms, and their trade-offs are covered in our guide to ED injections and devices. Emerging modalities such as shockwave therapy and PRP are also discussed across the cluster, with the honest caveat that their evidence base is still developing.
Provider training
Because PDE5 inhibitors are so widely requested, the clinical skill is less about whether to use them and more about using them well and safely: evaluating the patient, screening rigorously for nitrate and alpha-blocker interactions, recognizing erectile dysfunction as a cardiovascular signal, selecting among agents by onset and duration, counseling patients on the arousal requirement, and knowing the structured next steps when oral therapy fails. Done properly, this is also a meaningful clinical service line in a sexual-wellness market that continues to grow.
Empire's curriculum is built around exactly this kind of practical judgment, taught by Dr. Betsy Greenleaf, DO — the first board-certified female urogynecologist in the United States and Empire's Director of Anti-Aging — and situates oral therapy within the full diagnostic and treatment pathway for erectile and sexual dysfunction.
Train to treat erectile dysfunction with confidence
Empire Medical Training's Erectile Dysfunction & Sexual Dysfunction Training is a CME-accredited program covering the nitric oxide / cyclic GMP pathway, PDE5 inhibitor selection and safety, the nitrate contraindication, evaluation, and the full ladder of next-line options — taught by board-certified physician Dr. Betsy Greenleaf. Enroll in the course to add this to your practice.
Explore the ED Training Course →PDE5 inhibitors: frequently asked questions
What are PDE5 inhibitors?
PDE5 inhibitors are a class of oral medications that are first-line therapy for erectile dysfunction. They include sildenafil (Viagra), tadalafil (Cialis), vardenafil (Levitra), and avanafil (Stendra). They work by blocking the enzyme phosphodiesterase type 5, which allows the molecule cyclic GMP to accumulate, relaxing smooth muscle and increasing blood flow in the penis. They require sexual stimulation to produce an effect.
How do Viagra and Cialis work?
Both Viagra (sildenafil) and Cialis (tadalafil) inhibit the PDE5 enzyme. During sexual arousal, nerves release nitric oxide, which raises cyclic GMP and relaxes the smooth muscle of the penile blood vessels. PDE5 normally breaks cyclic GMP down. By blocking PDE5, these drugs let cyclic GMP accumulate, sustaining vasodilation and increased blood flow. The main difference between them is timing: sildenafil acts quickly and lasts a few hours, while tadalafil has a much longer duration.
What are the side effects of PDE5 inhibitors?
Common side effects are generally mild and reflect vasodilation elsewhere in the body: headache, facial flushing, nasal congestion, indigestion, and transient visual changes such as a blue tint. The most important safety issue is that PDE5 inhibitors are absolutely contraindicated with nitrates, because the combination can cause a dangerous, potentially fatal drop in blood pressure. Caution is also required with alpha-blockers, and prolonged erection (priapism) is a rare but urgent risk.
Who should not take PDE5 inhibitors?
PDE5 inhibitors must never be taken by patients using nitrate medications for chest pain or heart disease, as the combination can cause life-threatening hypotension. They require caution in patients on alpha-blockers, those with significant cardiovascular disease, and certain other conditions. Because erectile dysfunction can be an early warning sign of cardiovascular disease, every candidate should be evaluated by a qualified provider before prescribing.
What training do providers need to prescribe PDE5 inhibitors?
Structured education helps clinicians understand the nitric oxide and cyclic GMP pathway, agent selection and onset/duration differences, patient evaluation including cardiovascular risk, the nitrate and alpha-blocker contraindications, and what to do when oral therapy fails. Empire Medical Training offers a CME-accredited sexual dysfunction and erectile dysfunction training course developed by Dr. Betsy Greenleaf, DO.
Empire Rewards Wheel
Claim Your Prize!